TABLE 2.
Correlations of the baseline characteristics, habits, pre-existing conditions, and baseline symptoms of COVID-19 patients with the baseline and 3-month follow-up (FU) anti-SARS-CoV-2 IgM and IgG levels.
|
Anti-SARS-CoV-2 IgM antibody level
|
Anti-SARS-CoV-2 IgG antibody level
|
|||||||||||||||
|
Baseline
|
Follow-up
|
Baseline
|
Follow-up
|
|||||||||||||
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|||||||||
| Predictor | r | P | r | P | R | P | r | P | R | P | r | P | r | P | r | P |
| Age | 0.085 | 6.8e−2 | – | – | 0.075 | 1.1e−1 | – | – | 0.228 | 6.8e−7 | 0.304 | 6.6e−3 | 0.289 | 2.1e−10 | 0.273 | 9.8e−3 |
| Male sex | 0.006 | 9.0e−1 | – | – | 0.150 | 1.1e−3 | 0.150 | 1.1e−3 | 0.185 | 5.0e−5 | 0.310 | 5.8e−3 | 0.162 | 4.1e−4 | 0.422 | 1.5e−4 |
| Days since diagnosis | 0.038 | 4.1e−1 | – | – | 0.043 | 3.5e−1 | – | – | 0.150 | 1.1e−3 | 0.235 | 3.5e−2 | 0.133 | 3.7e−3 | – | – |
| Blood group AB | −0.056 | 2.9e−1 | – | – | −0.066 | 2.0e−1 | – | – | −0.123 | 1.8e−2 | – | – | −0.016 | 7.6e−1 | – | – |
| Body mass index | 0.005 | 9.2e−1 | – | – | −0.061 | 2.1e−1 | – | – | 0.089 | 6.7e−2 | – | – | 0.088 | 6.9e−2 | – | – |
| Smoking | 0.044 | 3.7e−1 | – | – | 0.000 | 1.0e+0 | – | – | −0.064 | 1.9e−1 | – | – | −0.035 | 4.8e−1 | – | – |
| Alcohol use | −0.048 | 3.3e−1 | – | – | 0.002 | 9.6e−1 | – | – | 0.018 | 7.2e−1 | – | – | 0.071 | 1.5e−1 | – | – |
| Opium use | −0.008 | 8.7e−1 | – | – | −0.039 | 4.3e−1 | – | – | −0.019 | 7.0e−1 | – | – | −0.053 | 2.8e−1 | – | – |
| Positive chest CT-scan | 0.045 | 7.4e−1 | – | – | 0.149 | 2.7e−1 | – | – | 0.363 | 5.5e−3 | 0.248 | 2.5e−2 | 0.442 | 5.9e−4 | 0.338 | 1.9e−3 |
| Systemic symptoms | 0.087 | 7.8e−2 | – | – | 0.053 | 2.6e−1 | – | – | 0.106 | 3.1e−2 | – | – | 0.112 | 1.7e−2 | – | – |
| Respiratory symptoms | 0.022 | 6.6e−1 | – | – | −0.004 | 9.3e−1 | – | – | 0.122 | 1.3e−2 | – | – | 0.015 | 7.5e−1 | – | – |
| Gastrointestinal symptoms | 0.128 | 8.9e−3 | 0.118 | 1.5e−2 | −0.021 | 6.6e−1 | – | – | 0.153 | 1.7e−3 | – | – | 0.014 | 7.6e−1 | – | – |
| Pregnancy | 0.178 | 1.6e−2 | – | – | 0.129 | 8.3e−2 | – | – | −0.002 | 9.8e−1 | – | – | −0.016 | 8.3e−1 | – | – |
| Heart disease | 0.090 | 6.4e−2 | – | – | 0.007 | 8.9e−1 | – | – | 0.098 | 4.5e−2 | – | – | 0.103 | 3.5e−2 | – | – |
| Hypertension | −0.013 | 7.8e−1 | – | – | −0.040 | 4.1e−1 | – | – | 0.031 | 5.3e−1 | – | – | 0.063 | 2.0e−1 | – | – |
| Lung disease | 0.026 | 5.9e−1 | – | – | −0.025 | 6.1e−1 | – | – | 0.046 | 3.5e−1 | – | – | 0.140 | 4.0e−3 | – | – |
| Asthma | 0.019 | 6.9e−1 | – | – | −0.035 | 4.8e−1 | – | – | 0.028 | 5.7e−1 | – | – | 0.018 | 7.2e−1 | – | – |
| Diabetes mellitus | 0.005 | 9.2e−1 | – | – | −0.002 | 9.7e−1 | – | – | 0.100 | 4.1e−2 | – | – | 0.156 | 1.3e−3 | – | – |
| Fatty liver disease | 0.080 | 1.0e−1 | – | – | −0.001 | 9.8e−1 | – | – | 0.144 | 3.2e−3 | – | – | 0.139 | 4.2e−3 | – | – |
| Cirrhosis | 0.182 | 1.8e−4 | 0.173 | 3.8e−4 | −0.015 | 7.7e−1 | – | – | 0.052 | 2.9e−1 | – | – | 0.015 | 7.7e−1 | – | – |
| Malnutrition | 0.082 | 9.4e−2 | – | – | 0.013 | 7.9e−1 | – | – | −0.013 | 8.0e−1 | – | – | 0.030 | 5.4e−1 | – | – |
| Inflammatory bowel diseases | 0.116 | 1.7e−2 | – | – | −0.033 | 5.1e−1 | – | – | −0.015 | 7.5e−1 | – | – | −0.014 | 7.8e−1 | – | – |
| Hepatitis B | 0.007 | 8.8e−1 | – | – | −0.026 | 6.0e−1 | – | – | −0.039 | 4.3e−1 | – | – | −0.029 | 5.5e−1 | – | – |
| Autoimmune hepatitis | 0.067 | 1.7e−1 | – | – | −0.029 | 5.5e−1 | – | – | 0.045 | 3.6e−1 | – | – | −0.028 | 5.7e−1 | – | – |
| Kidney disease | 0.099 | 4.3e−2 | – | – | −0.017 | 7.3e−1 | – | – | 0.089 | 7.0e−2 | – | – | 0.096 | 5.0e−2 | – | – |
CT: computed tomography, Ig: immunoglobulin, and SARS-CoV-2: novel severe acute respiratory syndrome coronavirus-2.
All r values standing significant either in univariate or multivariate analysis were shown as bold.